LABT (Lakewood-Amedex Biotherapeutics) ROE % Adjusted to Book Value: 0.00% (As of Mar. 2026)


LABT Lakewood-Amedex Biotherapeutics Inc LABT
8 GF Score
Price $3.55
View Full Analysis

What is Lakewood-Amedex Biotherapeutics ROE % Adjusted to Book Value?

Lakewood-Amedex Biotherapeutics LABT +2.33% 8 ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus rates LABT with a GF Score™ of 8/100.

Lakewood-Amedex Biotherapeutics's ROE % for the quarter that ended in Mar. 2026 was 0.00%. Lakewood-Amedex Biotherapeutics's PB Ratio for the quarter that ended in Mar. 2026 was N/A. Lakewood-Amedex Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was N/A.

Lakewood-Amedex Biotherapeutics ROE % Adjusted to Book Value Related Terms

Lakewood-Amedex Biotherapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Lakewood-Amedex Biotherapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Lakewood-Amedex Biotherapeutics ROE % Adjusted to Book Value Chart

Lakewood-Amedex Biotherapeutics Annual Data
Trend Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00

Lakewood-Amedex Biotherapeutics Quarterly Data
Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

LABT vs CURX, PBM, NCNA: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lakewood-Amedex Biotherapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Lakewood-Amedex Biotherapeutics's ROE % Adjusted to Book Value falls into.


LABT
8GF Score
Lakewood-Amedex Biotherapeutics Inc LABT
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Lakewood-Amedex Biotherapeutics ROE % Adjusted to Book Value Calculation

Lakewood-Amedex Biotherapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

Lakewood-Amedex Biotherapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / N/A
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of 0.00% mean?
Lakewood-Amedex Biotherapeutics (LABT) has a ROE % Adjusted to Book Value of 0.00% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lakewood-Amedex Biotherapeutics and its competitors.
Is Lakewood-Amedex Biotherapeutics' ROE % Adjusted to Book Value too high?
Lakewood-Amedex Biotherapeutics' current ROE % Adjusted to Book Value is 0.00%. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' ROE % Adjusted to Book Value compare to CURX and PBM?
Lakewood-Amedex Biotherapeutics' ROE % Adjusted to Book Value of 0.00% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. Lakewood-Amedex Biotherapeutics's current ROE % Adjusted to Book Value is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current ROE % Adjusted to Book Value of 0.00%. The current ROE % Adjusted to Book Value is 0.00%. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current ROE % Adjusted to Book Value is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Lakewood-Amedex Biotherapeutics Business Description

Address 8031 Cooper Creek Blvd, Unit 103, University Park, FL, USA, 34201
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score

Get the complete analysis for LABT

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.55
Price